Stockreport

Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD) [Yahoo! Finan...

ChromaDex Corporation  (CDXC) 
NASDAQ:AMEX Investor Relations: investors.chromadex.com
PDF LOS ANGELES, June 24, 2024 BUSINESS WIRE )--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD ) research, shares results fro [Read more]